SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
American Journal of Alzheimer's Disease and Other Dementias®
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Tsolaki, M.
Right arrow Articles by Kazis, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tsolaki, M.
Right arrow Articles by Kazis, A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Correlation of rCBF (SPECT), CSF tau, and congnitive function in patients with dementia of the Alzheimer's type, other types of dementia, and congrol subjects

M. Tsolaki, MD, PhD

Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece

V. Sakka, MD

Department of Neurology, NIMTS, Athens, Greece

G. Gerasimou, MD

Department of Nuclear Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece

N. Dimacopoulos, MD

Department of Neurology, NIMTS, Athens, Greece

O. Chatzizisi, MD

Department of Immunology, Aristotle University of Thessaloniki, Thessaloniki, Greece

K. N. Fountoulakis, MD, PhD

Department of Psychiatry, Aristotle University of Thessaloniki, Thessaloniki, Greece

G. Kyriazis, MD

Department of Immunology, Aristotle University of Thessaloniki, Thessaloniki, Greece

J. Papanastasiou, MD

Department of Neurology, NIMTS, Athens, Greece

A. Kazis, MD, PhD

Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece

Background. The diagnosis of Alzheimer's disease (AD) during life remains difficult and a definite diagnosis of AD relies on histopathological confirmation at post-mortem or by cerebral biopsy. It is well known that levels of tau proteins are consistently and significantly increased in the cerebrospinal fluid (CSF) of Alzheimer's patients versus levels in normal controls. However, the sole use of this biochemical marker as a test for AD is hampered by mediocre specificity, since tau concentrations may also be elevated in certain other neurological disorders (OND). Studies of the regional cerebral blood flow (rCBF) are widely performed because of their convenience and usefulness in a variety of neurological disorders. Most studies have reported high diagnostic accuracy for brain perfusion single-photon emission tomography (SPECT) in Alzheimer's disease.

Methods. In order to improve specificity, in this study, correlation of 99mTc-HMPAO SPECT scanning and CSF tau protein levels was made in 117 patients with AD, 67 patients with OND (26 of which had other dementias), and 23 age-matched controls. Means and standard deviations of tau protein levels were 297, 42 ± 221, 12 in AD patients and 78,07 ± 98, 51 in patients with OND (p = 0.0006). No correlation was noted between CSF tau protein levels and age, duration of the disease, and neuropsychological scores of mini-mental state examination (MMSE), Cambridge Cognitive Examination (CAMCOG), and Functional Rating Scale for Symptoms of Dementia (FRSSD).

Findings. There was a bilateral parietal and temporal hypoperfusion in patients with AD in SPECT in comparison to normal subjects (p < 0.05) and there was a statistical correlation between this hypoperfusion and neuropsychological tests, such as MMSE and CAMCOG (p < 0.01). There was no correlation between tau protein levels and hypoperfusion in SPECT.

Interpretation. Conclusively, the correlation between elevated levels of tau proteins and hypoperfusion in SPECT in AD patients therefore cannot improve the specificity of tests in AD and this means that the determination of CSF tau proteins levels is not a specific diagnostic test for AD.

Key Words: Alzheimer's disease • correlation • neuropsychological tests • SPECT • tau protein

American Journal of Alzheimer's Disease and Other Dementias®, Vol. 16, No. 1, 21-31 (2001)
DOI: 10.1177/153331750101600107


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




Advertisement